The estimated Net Worth of Vadim M. Sapiro is at least $6.07 Tisíc dollars as of 23 February 2018. Mr Sapiro owns over 1,400 units of Opgen Inc stock worth over $6,068 and over the last 7 years he sold OPGN stock worth over $0.
Mr has made over 1 trades of the Opgen Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,400 units of OPGN stock worth $2,828 on 23 February 2018.
The largest trade he's ever made was exercising 1,400 units of Opgen Inc stock on 23 February 2018 worth over $2,828. On average, Mr trades about 467 units every 0 days since 2018. As of 23 February 2018 he still owns at least 3,004 units of Opgen Inc stock.
You can see the complete history of Mr Sapiro stock trades at the bottom of the page.
Vadim Sapiro is the Chief Information Officer at Opgen Inc.
Mr Sapiro is 50, he's been the Chief Information Officer of Opgen Inc since . There are 5 older and 1 younger executives at Opgen Inc. The oldest executive at Opgen Inc is Dr. G. Terrance Walker Ph.D., 62, who is the Sr. VP of R&D.
Vadim's mailing address filed with the SEC is C/O OPGEN, INC. 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG, MD, 20878.
Over the last 9 years, insiders at Opgen Inc have traded over $12,018 worth of Opgen Inc stock and bought 4,331,782 units worth $1,198,700 . The most active insiders traders include Evan/ Fa Jones, Capital, Llcjones Evan/ Fa ... a Capital, Llc J Ven. On average, Opgen Inc executives and independent directors trade stock every 78 days with the average trade being worth of $280,277. The most recent stock trade was executed by Johannes Bacher on 31 March 2023, trading 6,434 units of OPGN stock currently worth $12,997.
opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.
Opgen Inc executives and other stock owners filed with the SEC include: